New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
08:10 EDTACST, NEPTAcasti Pharma presents preliminary data on NKPL66
Acasti Pharma (ACST), a Neptune Technologies & Bioressources (NEPT) subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 in the treatment of mild-to-high hypertriglyceridemia". In the course of planning the strategy of its phase III clinical development with CaPre, Acasti examined triglycerides data from its Open-label clinical trial.Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre per day were assessed and CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre were observed. To date, the results of this preliminary analysis suggest that CaPre is safe and effective for the treatment of patients with triglyceride levels ranging from 200 to 500 mg/dL.
News For ACST;NEPT From The Last 14 Days
Check below for free stories on ACST;NEPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
14:05 EDTNEPTNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTNEPTEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information
April 10, 2014
16:09 EDTNEPTGeorge Haywood reports 9.9% stake in Neptune Technologies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use